Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis

Therapeutic Effect Between Quetiapine and Haloperidol on the Treatment of Methamphetamine - Induced Psychosis

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01939093

Acronym

MAP

Enrollment

Registered

2013-09-11

Start date

2010-03-31

Completion date

2011-09-30

Last updated

2013-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Methamphetamine-induced Psychosis

Keywords

Quetiapine, Haloperidol, Methamphetamine, Psychosis

Brief summary

The aims of this study are to compare the antipsychotic and adverse events of quetiapine, an atypical antipsychotic drug, to haloperidol, a standard treatment for primary psychotic disorder, in individuals with MAP.

Detailed description

Eighty individuals with MAP will be randomly assigned into two treatment groups, i.e. treatment with quetiapine and haloperidol. The quetiapine group will receive quetiapine at least 100 mg per day and the haloperidol group will receive haloperidol at least 2 mg per day orally once a day for four weeks. The doses will be increased every 5 days until no psychotic symptom is observed from the Positive and Negative Syndrome Scale. Common antipsychotic adverse events will be checked and documented daily.

Interventions

DRUGDiazepam

If subjects had aggressive or violent symptoms and immediate symptom control was needed, 10 mg of diazepam (intravenous injection) every 4 hours is allowed for symptom control.

DIETARY_SUPPLEMENTVitamin B1-6-12

All subjects will be given the Institute's medication regimen, including vitamin B1-6-12 1 tablet three times a day after meals during the whole study period.

DRUGStugeron

All subjects will be given the Institute's medication regimen, including stugeron 1 tablet three times a day after meals during the whole study period.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Having a psychotic episode with current use of methamphetamine * Positive urine toxicology test for methamphetamine on the first day of hospitalization

Exclusion criteria

* Using other illegal substances * Having a history of primary psychotic disorders or using antipsychotic agents * Having a chronic medical disease, e.g. essential hypertension, diabetes, epilepsy, stroke

Design outcomes

Primary

Measure	Time frame
Positive and Negative Syndrome Scale	Every day in Week 1.

Secondary

Measure	Time frame
Antipsychotic Adverse Event Form	Every day for three weeks.

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026